Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00857948 · ClinicalTrials.gov registry record · Phase 2

Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation

A Phase 2 study, sponsored by Topaz Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
78
Enrollment target

NCT00857948 is a Phase 2 study that has completed, run by Topaz Pharmaceuticals. The registered enrollment target is 78 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00857948, a Phase 2 study, has completed, sponsored by Topaz Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
78 participants
Enrollment target

Study Summary

This is a Phase 2 single center study designed to compare the safety, local tolerability, and efficacy of 3 strengths of ivermectin treatment conditioner to placebo.

Interventions

  • DRUG Placebo, vehicle control
  • DRUG ivermectin treatment conditioner

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2009-03
Est. Completion 2009-04
Phase Phase 2

Sponsor

Topaz Pharmaceuticals

5 total trials

What the Registry Record Tells You About NCT00857948

The ClinicalTrials.gov registry entry for NCT00857948 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Topaz Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo, vehicle control is the first listed.

NCT00857948 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00857948 about?

NCT00857948 is a clinical study titled "Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation". This is a Phase 2 single center study designed to compare the safety, local tolerability, and efficacy of 3 strengths of ivermectin treatment conditioner to placebo.

What is the current status of trial NCT00857948?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2009-03. Estimated completion is 2009-04.

What interventions are being tested in trial NCT00857948?

The interventions under investigation include: Placebo, vehicle control (DRUG), ivermectin treatment conditioner (DRUG).

Who is sponsoring clinical trial NCT00857948?

This trial is sponsored by Topaz Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.